Novartis AG (NVS) Receives Average Rating of “Hold” from Brokerages

Shares of Novartis AG (NYSE:NVS) have been given an average rating of “Hold” by the eighteen research firms that are covering the company, Marketbeat.com reports. Three investment analysts have rated the stock with a sell rating, seven have assigned a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $90.94.

A number of brokerages have commented on NVS. JPMorgan Chase & Co. restated a “neutral” rating on shares of Novartis in a research note on Thursday, October 11th. Cowen upgraded shares of Novartis from a “market perform” rating to an “outperform” rating and set a $88.03 target price on the stock in a research report on Sunday, December 2nd. Zacks Investment Research upgraded shares of Novartis from a “hold” rating to a “buy” rating and set a $96.00 target price on the stock in a research report on Tuesday, December 18th. Barclays lowered shares of Novartis from an “equal weight” rating to a “sell” rating in a research report on Friday, December 7th. Finally, Credit Suisse Group lowered shares of Novartis to a “sell” rating in a research report on Thursday, December 20th.

Shares of NYSE:NVS traded down $0.50 during midday trading on Friday, hitting $87.61. 89,931 shares of the stock were exchanged, compared to its average volume of 2,352,422. The company has a current ratio of 1.20, a quick ratio of 0.96 and a debt-to-equity ratio of 0.29. Novartis has a 52-week low of $72.30 and a 52-week high of $94.19. The firm has a market cap of $200.88 billion, a price-to-earnings ratio of 18.22, a P/E/G ratio of 1.85 and a beta of 0.73.

Novartis (NYSE:NVS) last posted its earnings results on Thursday, October 18th. The company reported $1.32 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.31 by $0.01. The firm had revenue of $12.78 billion for the quarter, compared to the consensus estimate of $12.88 billion. Novartis had a net margin of 25.98% and a return on equity of 15.81%. The business’s quarterly revenue was up 2.9% on a year-over-year basis. During the same period in the prior year, the business posted $1.29 earnings per share. On average, sell-side analysts forecast that Novartis will post 5.22 EPS for the current year.

Several institutional investors have recently modified their holdings of the company. Bourgeon Capital Management LLC grew its stake in Novartis by 5.3% in the 3rd quarter. Bourgeon Capital Management LLC now owns 69,463 shares of the company’s stock worth $5,985,000 after buying an additional 3,490 shares in the last quarter. Raymond James Trust N.A. grew its position in shares of Novartis by 41.8% in the 3rd quarter. Raymond James Trust N.A. now owns 47,271 shares of the company’s stock worth $4,072,000 after buying an additional 13,938 shares during the period. Patton Albertson Miller Group LLC purchased a new stake in shares of Novartis in the 3rd quarter worth about $211,000. Aperio Group LLC grew its position in shares of Novartis by 12.4% in the 3rd quarter. Aperio Group LLC now owns 964,474 shares of the company’s stock worth $83,099,000 after buying an additional 106,560 shares during the period. Finally, First Fiduciary Investment Counsel Inc. grew its position in shares of Novartis by 0.3% in the 2nd quarter. First Fiduciary Investment Counsel Inc. now owns 227,371 shares of the company’s stock worth $17,176,000 after buying an additional 735 shares during the period. 11.18% of the stock is owned by institutional investors.

Novartis Company Profile

Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. This segment also commercializes products in the areas of oncology and rare diseases, ophthalmology, immunology and dermatology, neuroscience, respiratory, cardio-metabolic, and established medicines.

Featured Story: What impact do institutional investors have on markets?

Analyst Recommendations for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply